Profile data is unavailable for this security.
About the company
NanoViricides, Inc. is a clinical-stage company. The Company is engaged in developing a class of drugs that it calls nanoviricides, using a platform technology based on the application of nanomedicine technologies to the complex issues of viral diseases. Its lead drug candidate is NV-387, a broad-spectrum antiviral drug that has demonstrated activity in lethal lung infection animal model studies of Coronavirus (COVID), Respiratory Syncytial Virus, Influenza, Orthopoxvirus model for Smallpox and MPox, and even in a humanized mice model for Measles. It is focused on advancing Phase II clinical trials. Its other advanced drug candidate is NV-HHV-1 for the treatment of Shingles rash. Its NV-CoV-2 and NV-CoV-2-R are drug candidates for the treatment of COVID. Its portfolio also includes NV-HIV-1, a novel mechanism Anti-HIV Drug Candidate. Its other drug candidates include treatment for viral infections, including Dengue viruses, Ebola viruses, among others.
- Revenue in USD (TTM)0.00
- Net income in USD-8.13m
- Incorporated2023
- Employees7.00
- LocationNanoViricides, Inc1 Controls DriveSHELTON 06484United StatesUSA
- Phone+1 (203) 937-6137
- Fax+1 (302) 655-5049
- Websitehttps://www.nanoviricides.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Eom Pharmaceutical Holdings Inc | 0.00 | -4.93m | 17.71m | 3.00 | -- | -- | -- | -- | -0.0435 | -0.0435 | 0.00 | -0.0212 | -- | -- | -- | 0.00 | -- | -126.34 | -- | -171.37 | -- | -- | -- | -- | -- | -- | 7.41 | -- | -- | -- | -254.37 | -- | -- | -- |
| Klotho Neurosciences Inc | 0.00 | -11.29m | 17.72m | 3.00 | -- | 1.71 | -- | -- | -0.3264 | -0.3264 | 0.00 | 0.1411 | 0.00 | -- | -- | 0.00 | -180.10 | -- | -197.00 | -- | -- | -- | -- | -- | -- | -1.90 | 0.00 | -- | -- | -- | -556.89 | -- | -- | -- |
| P3 Health Partners Inc | 1.44bn | -131.05m | 18.45m | 360.00 | -- | -- | -- | 0.0128 | -40.18 | -40.18 | 442.85 | -5.72 | 1.91 | -- | 14.07 | 4,013,756.00 | -37.78 | -49.89 | -113.11 | -253.77 | -4.05 | -1.15 | -19.83 | -46.73 | -- | -5.36 | 0.9304 | -- | 18.48 | 59.38 | -135.14 | -- | -- | -- |
| Provectus Biopharmaceuticals Inc | 350.44k | -6.63m | 18.45m | 6.00 | -- | -- | -- | 52.65 | -0.0158 | -0.0158 | 0.0008 | -0.0146 | 0.5736 | -- | -- | 58,406.67 | -1,102.23 | -267.67 | -- | -- | -- | -- | -1,921.64 | -1,092.28 | -- | -27.00 | -- | -- | 10.66 | -- | -52.58 | -- | -- | -- |
| Vyne Therapeutics Inc | 524.00k | -33.79m | 18.56m | 13.00 | -- | 0.552 | -- | 35.41 | -0.7917 | -0.7888 | 0.0123 | 1.01 | 0.0093 | -- | -- | 40,307.69 | -60.16 | -107.54 | -70.67 | -136.47 | -- | -- | -6,448.47 | -1,720.83 | -- | -- | 0.00 | -- | 18.16 | -- | -42.82 | -- | 60.46 | -- |
| Lunai Bioworks Inc | 0.00 | -130.98m | 19.35m | 29.00 | -- | -- | -- | -- | -7.51 | -7.51 | 0.00 | -0.5626 | 0.00 | -- | -- | 0.00 | -203.39 | -75.79 | -304.47 | -85.18 | -- | -- | -- | -- | -- | -28.85 | -- | -- | -- | -- | -101.31 | -- | -- | -- |
| IN8bio Inc | 0.00 | -20.66m | 19.53m | 18.00 | -- | 0.6959 | -- | -- | -6.48 | -6.48 | 0.00 | 2.87 | 0.00 | -- | -- | 0.00 | -126.22 | -79.60 | -150.81 | -91.19 | -- | -- | -- | -- | -- | -- | 0.0299 | -- | -- | -- | -1.43 | -- | -10.74 | -- |
| Apimeds Pharmaceuticals US Inc | 0.00 | -5.16m | 19.62m | 2.00 | -- | 2.40 | -- | -- | -0.4762 | -0.4762 | 0.00 | 0.6489 | 0.00 | -- | -- | 0.00 | -111.07 | -- | -138.71 | -- | -- | -- | -- | -- | -- | -162.30 | 0.0577 | -- | -- | -- | -78.73 | -- | -- | -- |
| Anebulo Pharmaceuticals Inc | 0.00 | -8.44m | 19.78m | 2.00 | -- | 2.03 | -- | -- | -0.2354 | -0.2354 | 0.00 | 0.237 | 0.00 | -- | -- | 0.00 | -128.22 | -108.15 | -145.11 | -112.69 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -3.45 | -- | -- | -- |
| NanoViricides, Inc | 0.00 | -8.13m | 20.17m | 7.00 | -- | 2.29 | -- | -- | -0.5115 | -0.5115 | 0.00 | 0.4087 | 0.00 | -- | -- | 0.00 | -80.86 | -43.34 | -94.03 | -45.34 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -14.14 | -- | 45.82 | -- |
| Apollomics Inc | 8.50m | -31.19m | 20.96m | 13.00 | -- | -- | -- | 2.47 | -26.61 | -26.61 | 8.01 | -3.99 | 0.3721 | -- | -- | 653,846.10 | -136.51 | -- | -276.35 | -- | -- | -- | -366.92 | -- | -- | -- | -- | -- | -- | -- | 68.80 | -- | -- | -- |
| Polyrizon Ltd | 0.00 | -1.16m | 21.12m | 1.00 | -- | 0.7068 | -- | -- | -582.43 | -582.43 | 0.00 | 18.75 | 0.00 | -- | -- | 0.00 | -11.74 | -80.79 | -12.20 | -179.91 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -139.91 | -- | -- | -- |
| Jupiter Neurosciences Inc | 0.00 | -7.60m | 21.29m | 4.00 | -- | 369.28 | -- | -- | -0.2296 | -0.2296 | 0.00 | 0.0017 | 0.00 | -- | -- | 0.00 | -570.85 | -383.24 | -- | -- | -- | -- | -- | -902.90 | -- | -- | 0.7183 | -- | -- | -- | 49.00 | -- | -- | -- |
| Neuphoria Therapeutics Inc | 15.66m | -9.47m | 21.51m | 7.00 | -- | 0.7538 | -- | 1.37 | -3.77 | -3.77 | 8.42 | 5.31 | 0.6233 | -- | 266.10 | 2,237,532.00 | -37.69 | -35.39 | -44.48 | -39.01 | -- | -- | -60.47 | -375.66 | -- | -- | 0.0026 | -- | -- | 246.65 | 97.61 | -- | -- | -- |
| Finch Therapeutics Group Inc | 0.00 | -14.17m | 22.08m | 18.00 | -- | 1.55 | -- | -- | -8.82 | -8.82 | 0.00 | 8.86 | 0.00 | -- | -- | -- | -25.20 | -- | -28.80 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -87.57 | -- | 34.80 | -- | -- | -- |
| Vistagen Therapeutics Inc | 736.00k | -62.24m | 22.14m | 59.00 | -- | 0.3286 | -- | 30.08 | -1.91 | -1.91 | 0.0227 | 1.71 | 0.008 | -- | -- | 13,142.86 | -67.86 | -55.19 | -76.71 | -59.56 | -- | -- | -8,455.98 | -5,842.62 | -- | -- | 0.0098 | -- | -54.32 | -- | -75.12 | -- | -- | -- |
Data as of Feb 09 2026. Currency figures normalised to NanoViricides, Inc's reporting currency: US Dollar USD
6.09%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 31 Dec 2025 | 511.48k | 2.37% |
| Renaissance Technologies LLCas of 30 Sep 2025 | 210.50k | 0.98% |
| Geode Capital Management LLCas of 30 Sep 2025 | 159.43k | 0.74% |
| BlackRock Fund Advisorsas of 30 Sep 2025 | 158.75k | 0.74% |
| Vanguard Fiduciary Trust Co.as of 31 Dec 2025 | 90.39k | 0.42% |
| Susquehanna Financial Group LLLPas of 30 Sep 2025 | 52.22k | 0.24% |
| SSgA Funds Management, Inc.as of 30 Sep 2025 | 41.91k | 0.19% |
| Bridgeway Capital Management LLCas of 30 Sep 2025 | 36.04k | 0.17% |
| UBS Switzerland AG (Investment Management)as of 31 Dec 2025 | 29.87k | 0.14% |
| Northern Trust Investments, Inc.(Investment Management)as of 30 Sep 2025 | 24.26k | 0.11% |
More ▼
Data from 30 Sep 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
